Arch Biopartners Inc (ARCH_CDNX)
ARCH_CDNX moved a median of -0.59% 30 minutes after news, and 0.00% by the close. How ARCH_CDNX actually reacts to news — the realized, point-in-time move the market made, measured across 48 labeled events over the last three years with zero look-ahead.
ARCH_CDNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.32% | 19% | 21 |
| 30-min | -0.59% | 19% | 21 |
| 60-min | 0.00% | 38% | 21 |
| to close | 0.00% | 43% | 21 |
| Middle 50% of ARCH_CDNX reactions | -1.25% to 0.00% |
|---|---|
| Median reaction (30-min) | -0.59% |
| Measured reactions | 48 |
Half of all Arch Biopartners Inc news events land between -1.25% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ARCH_CDNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARCH_CDNX's baseline. Nothing else.
Recent ARCH_CDNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide | Press release | GlobeNewswire | — | — | |
| Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans | Press release | GlobeNewswire | — | — | |
| Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial | Press release | GlobeNewswire | — | — | |
| Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Closes Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Arranges Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Closes Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Arranges Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia | Press release | GlobeNewswire | — | — | |
| Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Closes Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Arranges Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) | Press release | GlobeNewswire | — | — | |
| Shares for Interest Debt Settlement | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | — | — | |
| Arch Biopartners Arranges Non-Brokered Private Placement | Press release | GlobeNewswire | — | — | |
| Closes Units for Debt Settlement | Press release | GlobeNewswire | — | — | |
| Units for Debt Settlement | Press release | GlobeNewswire | -0.58% | +2.34% | |
| Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | Press release | GlobeNewswire | +0.00% | +0.67% | |
| Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins | Press release | GlobeNewswire | -1.31% | +1.31% | |
| Arch Biopartners Closes Non-Brokered Private Placement | Press release | GlobeNewswire | +0.00% | -5.10% | |
| Arch Biopartners Arranges Non-Brokered Private Placement | Press release | GlobeNewswire | -0.63% | -1.88% | |
| Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product | Press release | GlobeNewswire | -1.18% | +0.00% | |
| Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) | Press release | GlobeNewswire | -1.18% | -1.18% | |
| St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | -0.84% | -1.67% | |
| UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | +0.00% | -0.83% | |
| Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | -1.65% | -1.65% | |
| Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2 | Press release | GlobeNewswire | -2.52% | +4.62% | |
| University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | +2.49% | +9.45% | |
| Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | -0.32% | +10.90% | |
| Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury | Press release | GlobeNewswire | +1.89% | +0.63% | |
| Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | +1.42% | +2.13% | |
| Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | Press release | GlobeNewswire | -0.67% | -2.69% | |
| Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide | Press release | GlobeNewswire | -5.00% | +7.14% | |
| Grant of Options to Directors and Officers | Press release | GlobeNewswire | +2.04% | +0.00% | |
| Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide | Press release | GlobeNewswire | +0.00% | -4.00% | |
| Shares for Interest Debt Settlement | Press release | GlobeNewswire | +0.00% | -2.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARCH_CDNX section they belong to.
Where else ARCH_CDNX is measured.
ARCH_CDNX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | 49 | 0.00% | 49% |
| Advaxis, Inc. (ADXS) | 48 | 0.00% | 21% |
| SINO BIOPHARM ORD (SBMFF) | 48 | 0.00% | 4% |
| Theralase Technologies Inc (TLT_CDNX) | 48 | 0.00% | 18% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arch Biopartners Inc's median reaction calculated?
Every labeled ARCH_CDNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 48 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 19% of ARCH_CDNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARCH_CDNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.